Cardiff Oncology Inc. buy FXX
Start price
17.10.20
/
50%
€12.90
Target price
04.11.21
-
Performance (%)
-29.07%
End price
24.03.21
€9.15
Summary
This prediction ended on 24.03.21 with a price of €9.15. The prediction for Cardiff Oncology Inc. disappointed with a performance of -29.07%. FXX has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Cardiff Oncology Inc. | -1.991% | -1.991% | 105.392% | -58.974% |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
According to FXX what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Normal challenges to pay loans and raise capital
Some uniques
Small cyclical dependencies
High dividend yield expected
Cons
Risky balance sheet
Comments by FXX for this prediction
In the thread Trovagene diskutieren
Buy Cardiff Oncology Inc.